Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience.
Rohan ShottonRachel BroadbentAlia AlchawafMohamed Bakri MohamedAdam GibbNicolás Martinez-CalleChristopher Paul FoxMark BishtonAlexandra PenderMary GleesonDavid CunninghamAndrew John DaviesSina YadollahiToby Andrew EyreGraham P CollinsFaouzi DjebbariShireen KassamPaula GarlandEmily WattsWendy OsborneWiliam M TownsendRachael PocockMatthew J AhearneFiona MiallXin WangKim M LintonPublished in: Blood advances (2023)
In this real-world analysis, bendamustine-related deaths and treatment discontinuation were similar to trial populations of younger, fitter patients. Poor PS, mantle cell histology and maintenance rituximab were potential risk factors. Infections, including late onset events, were the most common treatment-related SAE and cause of death warranting extended antimicrobial prophylaxis and infectious surveillance, especially in maintenance-treated patients.
Keyphrases
- end stage renal disease
- late onset
- newly diagnosed
- risk factors
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- clinical trial
- prognostic factors
- early onset
- randomized controlled trial
- patient reported outcomes
- staphylococcus aureus
- single cell
- climate change
- study protocol
- chronic lymphocytic leukemia
- replacement therapy
- phase iii
- patient reported